Drugs like Ozempic and Wegovy earned their fame by shrinking waistlines and steadying blood sugar. A new analysis in Nature Communications asks a larger question: does semaglutide, the compound behind them, also touch the biology of ageing itself? The answer, for now, is a carefully hedged yes – and the hedges matter as much as the finding.
Researchers at the University of California San Diego and partner institutions went back to a completed 32-week, randomised, double-blind, placebo-controlled trial in adults living with HIV-associated lipohypertrophy, a condition in which fat builds up around the abdomen. Blood from 84 participants was available – 45 who had received weekly semaglutide injections, 39 who had received placebo. The team measured DNA methylation, the pattern of chemical tags that switches genes on and off, at the start and again at week 32.
Methylation is the raw material for so-called epigenetic clocks, which estimate how fast a body is ageing rather than how many birthdays it has had. Across several of the newer clocks, the semaglutide group aged measurably more slowly than the placebo group. On PhenoAge the gap came to 4.9 years; on PCGrimAge, a measure tied to age-related disease and mortality risk, 3.1 years. DunedinPACE, which tracks the ongoing pace of ageing, ran about 9 percent slower. Clocks built around specific organ systems moved in the same direction, most clearly for inflammation, brain and heart.
Why the caveats are the story
This is the first evidence from a randomised, placebo-controlled human trial that a GLP-1 drug shifts validated markers of biological ageing. It is also, by the authors' own account, a post hoc exploratory analysis: ageing was never what the original trial set out to measure. That study was designed to test the drug's effect on visceral fat. The sample is modest, everyone in it was living with HIV, and the follow-up lasted eight months. None of that makes the signal false; it makes it a lead rather than a conclusion.
The reason it is a plausible lead lies in mechanism. People with HIV tend to age faster biologically even when antiviral therapy keeps the virus in check, and chronic immune activation is thought to be a major driver. GLP-1 drugs damp down inflammation and strip out visceral and ectopic fat – the deposits that sit deep around organs, or in tissues where fat has no business being. Both reduce the inflammatory signalling that pushes ageing along. First author Michael Corley, of the UC San Diego School of Medicine and the Stein Institute for Research on Aging, notes that emerging data suggest the drugs may also reprogram cells across different organs, which could explain why so many clocks moved together.
What would settle it is a trial built for the purpose, in a broader population, running for longer. The researchers say so themselves. For a class of medicines already in millions of medicine cabinets, that is a question worth answering properly.